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The Mental Health Biomarker Project (2010–2016) explored variables for psychosis in 
schizophrenia and schizoaffective disorder. Blood samples from 67, highly characterized 
symptomatic cases and 67 gender and age matched control participants were analyzed 
for methyl tetrahydrofolate reductase (MTHFR) 677C → T gene variants and for vitamin 
B6, B12 and D, folate, unbound copper, zinc cofactors for enzymes in the methylation 
cycle, and related catecholamine pathways. Urine samples were analyzed for indole- 
catecholamines, their metabolites, and oxidative-stress marker, hydroxylpyrolline-2-one 
(HPL). Rating scales were Brief Psychiatric Rating Scale, Positive and Negative 
Syndrome Scale, Global Assessment of Function scale, Clinical Global Impression (CGI) 
score, and Social and Occupational Functioning Assessment Scale (SOFAS). Analysis 
used Spearman’s correlates, receiver operating characteristics and structural equation 
modeling (SEM). The correlative pattern of variables in the overall participant sample 
strongly implicated monoamine oxidase (MAO) enzyme inactivity so the significant role 
of MAO’s cofactor flavin adenine nucleotide and its precursor flavin adenine mononucle-
otide (FMN) within the biochemical pathways was investigated and confirmed as 71% 
on SEM of the total sample. Splitting the data sets for MTHFR 677C → T polymorphism 
variants coding for the MTHFR enzyme, discovered that biochemistry variables relating 
to the wild-type enzyme differed markedly in pattern from those coded by the homozy-
gous variant and that the hereozygous- variant pattern resembled the wild-type-coded 
pattern. The MTHFR 677C → T-wild and - heterozygous gene variants have a pattern of 
depleted vitamin cofactors characteristic of flavin insufficiency with under-methylation 
and severe oxidative stress. The second homozygous MTHFR 677TT pattern related 
to elevated copper:zinc ratio and a vitamin pattern related to flavin sufficiency and risk 
of over-methylation. The two gene variants and their different biochemical phenotypes 
govern findings in relationship to case- identification, illness severity, duration of illness, 
and functional disability in schizophrenia and schizoaf fective psychosis, and establish 
a basis for trials of gene-guided precision treatment for the management of psychosis.
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inTrODUcTiOn
The Mental Health Biomarker Project (MHBP, 2010–2013 and 
ongoing) was designed to discover and explore biomarkers 
capable of discriminating between those participants with and 
without a functional psychosis condition, as mainly represented 
by schizophrenia and schizoaffective disorder. Candidate mark-
ers had already been explored by pilot study (Section S1 in 
Supplementary Material) with promising results. These and other 
candidate markers were selected for assay and results examined 
by receiver operating characteristic (ROC) curve analysis in order 
to discover their biomarker status. Then, the most outstanding 
biomarkers were incorporated into a model for case-detection 
and prediction for screening purposes (1).
As part of the biomarker exploration component of this 
project, biomarkers of the functional psychosis model were 
examined for their predictive translational relationships. As a 
result, biochemistry-nutrition domain biomarkers were found to 
exert subtle, yet fundamental cumulative effects on neurotrans-
mitter synthesis and metabolism (2). Such biomarkers possessed 
significant interactions with each other in domains representing 
elevated catecholamines, oxidative stress, and visual and auditory 
processing abnormalities. Schizophrenia and schizoaffective psy-
chosis was, therefore, confirmed to be a composite, multi-domain 
entity where nutrition-related biomarkers exert the strongest 
overall predictive influence on all other biomarker domains. This 
fundamental biochemistry domain was, therefore, considered to 
be an important entity requiring further exploration.
The MHBP found particular biomarkers for low folate, vitamin 
B6, and vitamin D (1) that have known epidemiological links with 
schizophrenia (3). Hydroxyhemopyrroline-2-one (HPL) was 
also found to be a biomarker and this is a theoretical indicator 
of oxidative stress and disturbed porphyrin synthesis with heme-
degredation in schizophrenia (4). A further significant finding 
from the MHBP was that noradrenaline (NA), adrenaline (AD), 
and their metabolic product methoxy-hydroxymandelic acid 
(MHMA), when configured as NA/MHMA and AD/MHMA, 
to represent activity of their metabolizing enzyme monoamine 
oxidase (MAO), formed highly significant biomarkers for schizo-
phrenia and schizoaffective psychosis. This finding highlighted 
the need to analyze variables and biomarkers relating to MAO 
activity and its flavin cofactor (FAD) in relationship to catechola-
mine turnover and caseness for functional psychosis (1, 2).
Figure  1 depicts known interactive biochemical pathway 
relationships derived from research literature sources. In a bicyclic 
process referred to as one-carbon metabolism, the folate cycle is 
coupled to the methionine (methylation) cycle through the genera-
tion of 5-methyl-THF (MTHF) by the flavin-dependent enzyme 
methyl tetrahydrofolate reductase (MTHFR). Protein for this 
enzyme is coded by the MTHFR 677 C → T gene where Cytosine 
may be replaced by thymidine at the 677 position (5). Through 
metabolism of homocysteine (HCY) at the methionine synthase 
(MS) junction point between the folate and methionine cycles, 
MTHF donates a carbon to HCY to generate methionine, which in 
turn generates S-adenosylmethionine (SAMe). As a major methyl 
donor in cells, SAMe contributes to histone, DNA and RNA meth-
ylation and, therefore, to epigenetic regulation of gene expression 
(6, 7). SAMe is also an important cofactor for the second step of 
catechol-o-methyl transferase (COMT) metabolism of catechola-
mines as well as a cofactor for conversion of NA to AD (8). At 
the bottom of the methylation cycle, the vitamin B6-dependent 
transsulfuration pathway is connected to the methionine cycle 
through HCY, leading to the generation of cysteine and eventu-
ally glutathione, one of the major redox-regulating agents in cells 
(9). In addition, interactions between free copper, vitamin B6, 
catecholamine synthesis, and glutathione synthesis pathways have 
been outlined in literature reviews (10, 11).
MaTerials anD MeThODs
A full outline of Section “Materials and Methods” for this study 
can be found in previously published papers (1, 2), and a brief 
summary is given below for the interest of readers.
This study was approved by the Queen Elizabeth Hospital 
Research Ethics Committee (No: 2009139) and protocols and 
methods conformed to that committee’s regulatory standards. The 
author reports no conflict of interest at the time of undertaking 
this research or writing this paper. A provisional patent applica-
tion was filed in September 2016. Participants were assessed at 
the Queen Elizabeth Hospital and the Basil Hetzel Institute for 
Translational Health at Woodville, South Australia and two satel-
lite psychiatric clinics in the Western Adelaide community catch-
ment area (for further information, see Section “Investigation of 
MTHFR 677TT Gene Status in Relationship to Key Variables 
Using a Split Data Set”). Though the study was designed to be 
completed within 3  years, with data collection between May 
2010 and December 2014, the study has been extended to assess 
a further catchment area and is still ongoing.
Recruitment of patients with schizophrenia and schizoaffec-
tive disorder and controls lacking these disorders was from multi-
ethnic backgrounds in an age-range between 18 and 60 years. The 
aim of recruitment was to impose sufficient exclusion criteria to 
minimize confounding variables and strip psychosis in the case 
sample as far as possible down to its bare functional form (S2). In 
this way, potential confounding effects of substance abuse, organic 
causes, and medication were minimized and candidate markers 
that have strong discrimination and case-detection efficacy for 
functional psychosis could be exposed and be matched for age 
and sex with control participants.
Antipsychotic medication remained stable during the assess-
ment period and DSM IV-R criteria (12) case diagnoses were 
made by trained staff and checked by consensus opinion and 
DSM IV-R symptom-checklist. Patients and controls were rated 
Abbreviations: AD, adrenaline; BHMT, betain-homocysteine S-methyltransferase; 
Ca+, +Calcium; CBS, cystathione beta synthase; COMT, catechol-o-methyltrans-
ferase; Cp, ceruloplasmin; DA, dopamine; DAO, diamine oxidase; DOI, duration 
of illness; FAD, flavin dinucleotide; FMN, flavin mononucleotide; GSH, reduced 
(active) glutathione; GSI, Global Severity Index; GSSH, oxidized form of glutathione; 
HCY, homocysteine; HPL, hydroxypyrroline-2-one; MAO, monoamine oxidase; 
MHMA, methylhydroxymandelic acid; MS, methionine synthas; MTHF, 5-methyl 
tetrahydrofolic acid (active form of folate) produced by the MTHFR enzyme; 
MTHFR, 5,10-methylenetetrahydrofolate reductase enzyme; NA, Noradrenaline; 
SAMe, S-adenosyl homocysteine; SIR, symptom intensity rating; SOFAS, social 
and occupational functioning assessment scale; Vitamin B2, riboflavin.
FigUre 1 | a diagrammatic outline of the biochemical territory covered in the MhBP and presented in this manuscript. Enzymes: BHMT, betaine 
homocysteine methyltrasferase; COMT, catechol-o-methyl-transferase; CBS, cystathione beta synthase, MAT, methionine adenosyltransferase, MTHFR, 
methylenetetrahydrofolate reductase, SAMe, S-denosylmethionine, MT, methyltransferase, SAHH, S-adenosylhomocysteine-hydrolase, MSR, methionine sulfoxide 
reductase, MS, methionine synthase. Vitamin cofactors: vitamin B6 (pyridoxine), vitamin B12 (cobalamin), vitamin C, folic acid, 5 methyl tetrahydrofolate. Mineral 
enzyme cofactors: free (unbound) copper (Cu), zinc. Intermediate substrates: BH4, tetrahydrobiopterin BH2 – dihydrobiopterin; DMG, Dimethylglycine; DOPAL, 
dihydroxyphenylacetaldehyde; DOPAC, dihydroxyphenylacetic acid; DOPEGAL, dihydroxyphenylglycolaldehyde; DOMA, dihydroxymandelic acid; DHPG, 
dihydroxyphenylglycal; DOPA, dihydroxyphenylalanine; FAD, flavin adenine dinucleotide, 5HIAA, 5-hydroxyindolacetic acid, HVA, homovanillic acid, MAO, 
monoamine oxidase; MHMA, 3-methoxy-4-hydroxymandelic acid; MHPG, 4-hydroxy-3-methoxyphenylglycol; SAH, S-adenosylhomocysteine; TMG, 
trimethylglycine, VMA, vanillylmandelic acid. HPL, urinary hydroxyhemopyrroline-2-one.
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for clinical and subclinical symptoms, respectively, and had 
biological samples taken prior to auditory and visual process-
ing assessments. Control participants were randomly letter and 
phone-recruited from participants in the North West Adelaide 
catchment area after age and sex – stratified based upon patient 
recruitment data. Similar exclusion criteria as for patient 
recruitment were imposed and though no control participants 
possessed a diagnosis of mental illness, they were rated for 
subclinical symptoms in a similar manner to case participants. 
Further information on this process can be found in Sections S2, 
S3 in Supplementary Material.
Participants were assessed in a real-world setting, by psychiat-
rically trained assessors who were not blind to their participants’ 
status but were blind to their laboratory and sensory process-
ing status. Demographic data and information regarding risk 
predictors for schizophrenia or schizoaffective disorder (such 
as presence or absence of a family history of schizophrenia, 
depression or mania, developmental disorder history or learn-
ing disorder history, history of ear infection, premorbid sub-
clinical (non-concussed) head injury, hospitalization-frequency, 
disability-pension-status), was collected prior to rating scale 
assessments. Outcome measure ratings utilized the Clinical 
Global Impressions Scale (CGI) for severity, Global Assessment 
of Function (GAF), Social and Occupational Functioning 
Assessment Scale (SOFAS), and symptoms were rated using the 
Brief Psychiatric Rating Scale (BPRS) amalgamated with the 
Positive and Negative Syndrome for schizophrenia (PANSS) 
(S3). A symptom intensity rating (SIR, rated 1–7) was derived 
for each symptom and taken as an additional measure of clinical 
severity.
TaBle 1 | nutritional biochemistry domain, elevated catecholamine and oxidative stress domain rOcs, with respect to functional measures of disability 
and severity.
Domain rOcs case versus 
control
sOFas rOc gaF rOc cgi rOc hospital admission  
rate
Disability pension  
requirement
symptom intensity  
rating (sir)
High catecholamines 0.598 0.591 0.562 0.591 0.583 0.460 0.4677
Nutrition-related biochemistry 0.458 0.415 0.415 0.415 0.403 0.309 0.404
Oxidative stress (HPL/creatinine) 0.339 0.312 0.315 0.312 0.421 0.296 0.327
All rho values are significant at 95% level of confidence. For rho ≥ 0.350, P ≤ 0.0001.
SOFAS, social and occupational function scale. GAF, Global Assessment of Function Scale. CGI, Clinical Global Index (of Severity). Hospital admission rate as determined by number 
of admissions divided by duration of illness and Disability Pension receipt, as an index of cost burden.
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Candidate biochemical markers were selected based on pilot 
study results and for citations already-outlined in the Section 
“Introduction.” Standardized collection methods, protocols, and 
citations are documented in Sections S4 and S5 in Supplementary 
Material. Blood was assayed by commercial laboratories for 
vitamin B6, vitamin B12, red cell folate, plasma HCY, serum 
copper, serum ceruloplasmin, red cell zinc, serum histamine, 
methyltetrahydrofolate reductase (MTHFR 677 C →  T) gene 
polymorphism, and vitamin D. Urine assays were for levels of 
creatinine, dopamine (DA), NA, AD, and two of their metabolites 
[homovanillic acid (HVA), MHMA] as well as the serotonin 
metabolite 5-hydroxyindoleacetic acid (5-HIAA) and the oxida-
tive stress biomarker HPL.
Background analysis and results
Sample characteristic analysis, including characteristics related 
to medication and risk factors had previously been examined 
using XLSTAT (13) and STATA software (14). ROC curve analy-
sis (15, 16) used both XLSTAT and STATA software in order to 
discover which candidate markers met criteria for biomarkers of 
schizophrenia and schizoaffective disorder.
Due to implementation of the multiple exclusion criteria and 
an eligible participant consent rate of only 1 in 4, recruitment 
was slow and unpredictable, however, the process did result in 
a highly characterized group of patients becoming enrolled in 
the study and final data analysis was based on data from 67 
cases and 67 control participants. The biochemical biomarker 
results are summarized in S6. A full report of results from this 
study can also be found in Fryar-Williams and Strobel (1, 2). 
Details of catchment area characteristics, recruitment process 
outcomes, participant medications and data imputation can be 
found in S7. On Spearman’s correlation analysis, the nutritional-
biochemical domain ROC held highly significant correlates 
with outcome measures for functional psychosis severity (CGI 
and SIR), disability (GAF, disability pension and SOFAS) 
and hospital admission rate (at 95% level of significance) (1) 
(Table 1).
Further statistical analysis
Spearman’s correlation analysis (17) was first performed to 
explore and understand relationships between candidate 
marker levels and compound ROC variables in relationship to 
all other biochemical variables (Tables 2–4). Structural equation 
modeling (SEM) was secondly performed using STATA software 
(14) to examine the predicted role of Riboflavin-related flavin 
compounds FMN and FAD as intermediary variables in the bio-
chemical pathways of interest (Figure 2; Table 5). SEM analysis 
employs a system of simultaneous equations to determine to 
what degree the overall sample data support the linkage of any 
putative independent variable to other dependent variables in 
the data set and in the pathway of the model. Goodness of fit 
coefficient (R2) of the putative model is then calculated as a 
measure of percentage variation in the data. Finally, Spearman’s 
correlation analysis (17) was conducted on three data-sets, 
after data had been split three ways according to MTHFR 677 
C → T genotype (wild type, heterozygous polymorphism type, 
or homozygous polymorphism type). The data-sets so obtained 
were examined in relationship to other variables as well as 
caseness and functional measures for severity (CGI), symptom 
intensity (SIR), disability (GAF), and social and occupational 
function (SOFAS) (Tables  6 and 7). Dynamic understandings 
derived from these three different levels of data analysis were 
then collated and aligned in order to obtain overall perspective 
of the dynamics at work within the biochemistry of schizophre-
nia and schizoaffective psychosis.
Further results
When results from the full sample correlation analysis 
(Tables 2–4) were considered together with NA/MHMA and 
AD/MHMA ROCs (S8), (that reflected catecholamine metab-
olism by MAO) these ROCs were found significantly related 
to elevated NA (n = 133, rho = 0.673, P = 0.0000), elevated 
AD (n = 130, rho = 0.712, P = 0.0000), respectively (S7) (1). 
NA/MHMA and AD/MHMA ROCs were also significantly 
related to case-ness for psychosis (n  =  133, rho  =  0.505, 
P =  0.000) and (n =  130, rho =  0.483, P =  0.000), respec-
tively. Moreover, if low SAMe levels and COMT inhibition 
due to low MTHFR activity with reduced 5MTHF methyla-
tion product and ensuing insufficient SAMe production for 
histamine-metabolism, were to be the major explanation for 
elevated NA and AD, then both of their should also hold a 
significant correlative relationship with high histamine (but 
they did not) (Figure  1; Table  3). For these reasons, there 
must be some other factor operating in functional psychosis 
to explain the low catecholamine turnover by the metaboliz-
ing enzyme MAO. Since the other factor likely to influence 
MAO turnover is an absolute or functional deficiency of its 
co-factor flavin adenine nucleotide (FAD), it was reasonable 
TaBle 2 | Total sample correlation analysis for biochemical variables.
candidate marker variables VitD rc  
folate
B6 se  
B12
Free  
cu/Zn
Vit D rc  
folate
B6 se  
B12
Free  
cu/Zn
MThFr 
homozygous
Caseness Correlation coefficient −0.262 −0.268 −0.240 0.113 0.141 AD −0.248 −0.210 −0.187 −0.019 −0.011
Sig. (two-tailed) 0.002 0.002 0.006 0.195 0.103 0.004 0.015 0.034 0.825 0.901
N 132 133 129 134 134 131 132 128 133 133
SIR index Correlation coefficient −0.209 −0.209 −0.124 0.192 0.082 AD/MHMA −0.186 −0.186 −0.118 −0.030 −0.050
Sig. (two-tailed) 0.016 0.016 0.162 0.026 0.345 0.036 0.035 0.189 0.737 0.571
N 132 133 129 134 134 128 129 125 130 130
GAF Correlation coefficient 0.234 0.335 0.335 0.230 −0.061 HPL/CREAT −0.137 −0.033 −0.066 0.104 −0.030 −0.181
Sig. (two-tailed) 0.009 0.000 0.000 0.165 0.499 0.120 0.704 0.456 0.232 0.731 0.037
N 122 123 123 124 124 131 132 128 133 133 133
CGI Correlation coefficient −0.276 −0.275 −0.205 0.140 0.112 Plasma HCY −0.036 −0.213 −0.188 −0.049 −0.052 0.224
Sig. (two-tailed) 0.002 0.002 0.025 0.121 0.216 0.683 0.015 0.033 0.581 0.551 0.009
N 122 123 119 124 124 130 131 128 132 132 134
SOFAS Correlation coefficient 0.216 0.286 0.259 −0.120 −0.072 Free Cu/Zn 0.008 0.062 −0.125 −0.060 1.000
Sig. (two-tailed) 0.017 0.001 0.004 0.184 0.424 0.928 0.478 0.157 0.493  
N 122 123 119 124 124 132 133 129 134 134
DA Correlation coefficient −0.236 −0.212 −0.102 −0.057 −0.097 B6 0.120 0.355 1.00 0.301 −0.125
Sig. (two-tailed) 0.007 0.015 0.254 0.516 0.266 0.178 0.000 0.001 0.157
N 131 132 128 133 133 127 128 129 129 129
DA/HVA Correlation coefficient −0.107 −0.180 −0.099 −0.176 0.039 Se B12 0.079 0.112 0.301 1.00 −0.060
Sig. (two-tailed) 0.223 0.039 0.264 0.043 0.655 0.371 0.198 0.001 0.493
N 131 132 128 133 133 132 133 129 134 134
NA Correlation coefficient −0.298 −0.224 −0.247 −0.031 0.005 RC folate 0.257 1.000 0.355 0.112 0.062
Sig. (two-tailed) 0.001 0.010 0.005 0.723 0.957 0.003 0.000 0.198 0.478
N 131 132 128 133 133 131 133 128 133 133
NA/MHMA Correlation coefficient −0.198 −0.167 −0.203 −0.035 0.002 Vit D 1.00 0.257 0.120 0.079 0.008
Sig. (two-tailed) 0.025 0.059 0.023 0.695 0.984 0.003 0.178 0.371 0.928
N 128 129 125 130 130 132 131 127 132 132
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to assume that FAD insufficiency or its precursor Flavin ade-
nine mononucleotide (FMN) may constitute an exogenous, 
unobserved variable influencing basement biochemistry of 
schizophrenia and schizoaffective disorder. Since FAD and 
its precursor FMN are derivatives of Riboflavin (Vitamin B2) 
riboflavin deficiency may also play an important role in the 
basement biochemistry of functional psychosis (see discus-
sion section). Accordingly, SEM of the biochemistry data was 
undertaken to understand how FMN–FAD might relate to 
other dependent variables of significance.
Using FMN–FAD as the independent variable, the SEM model 
result is shown in Table 5. Overall goodness of fit (R2) for this 
model was 0.707, meaning that FMN–FAD explains 71% of the 
variance of the dependent biochemical variables. The SEM model 
also satisfyingly confirmed that significant negative covariance z 
scores exist between FMN–FAD and:
 – Caseness for functional psychosis (n  =  134, z  =  −2.95, 
P = 0.003),
 – Symptom Intensity Rating (n = 134, z = −2.69, P = 0.007), and
 – Duration of Illness (DOI) (n = 134, z = −2.88, P = 0.004).
The below SEM results imply that low levels of FMN–FAD are 
strongly related to high case ness, high symptom intensity (SIR) 
and longitudinal duration of illness (DOI) in schizophrenia and 
schizoaffective disorder, in the participant sample of this study. 
Though the valence of the z coefficient in the SEM model is deter-
mined to some extent by the model structure, given the goodness 
of fit of the model, it was interesting to observe the strength of 
significant z coefficients within the model. Their implications 
discussed in the discussion section, below.
collated results of correlative and seM 
analysis for individual Variables within the 
Full Participant sample
Total Sample Correlation and SEM Analysis Results 
Imply FMN–FAD Insufficiency Linked to Elevated 
Catecholamine Levels
 – caseness and NA/MHMA (n = 130, rho = 0.514, P = 0.000).
 – caseness and NA/MHMA ROC (n  =  133, rho  =  0.505, 
P = 0.000).
 – caseness and AD/MHMA (n = 130, rho = 0.503, P = 0.000).
 – caseness and AD/MHMA ROC (n  =  130, rho  =  0.483, 
P = 0.000).
 – On SEM analysis, inverse findings were found between 
FAD and NA/MHMA (n  =  134, z  =  −3.01, P  =  0.003), 
FAD and AD/MHMA (n = 134, z = −3.08, P = 0.002), NA/
TaBle 3 | Total sample correlation matrix results for rOc biochemistry variables in relationship to each other.
rOc biochemistry variable 
correlates
low  
VitD rOc 
aUc = 0.65
low rc 
folate rOc 
aUc = 0.654
low B6 rOc 
aUc = 0.638
high se B12 rOc 
aUc = 0.565  
(sig 80%)
high Free 
cu:Zn × 100 rOc 
aUc = 0.611
MThFr_
hom
high  
hisT rOc 
aUc = 0.576
Caseness Correlation coefficient 0.268 0.31 0.3 0.146 0.225 −0.034 0.164
Sig. (two-tailed) 0.002 0 0.001 0.093 0.009 0.7 0.058
N 132 133 129 134 133 134 134
SIR Index Correlation coefficient 0.243 0.258 0.162 0.236 0.158 −0.003 0.147
Sig. (two-tailed) 0.005 0.003 0.066 0.006 0.069 0.975 0.091
N 132 133 129 134 133 134 134
GAF Correlation coefficient −0.243 −0.377 −0.251 −0.122 −0.109 0.023 −0.074
Sig. (two-tailed) 0.007 0 0.006 0.176 0.23 0.801 0.411
N 122 123 119 124 123 124 124
CGI Correlation coefficient 0.302 0.309 0.231 0.143 0.145 −0.021 0.113
Sig. (two-tailed) 0.001 0.001 0.012 0.112 0.109 0.815 0.212
N 122 123 119 124 123 124 124
SOFAS Correlation coefficient −0.243 −0.33 −0.286 −0.13 −0.124 0.022 −0.075
Sig. (two-tailed) 0.007 0 0.002 0.149 0.173 0.812 0.408
N 122 123 119 124 123 124 124
HPL/creatinine Correlation coefficient 0.091 0.021 0.061 0.064 0.098 −0.181 0.041
Sig. (two-tailed) 0.299 0.813 0.493 0.465 0.266 0.037 0.637
N 131 132 128 133 132 133 133
High DA ROC 0.244 0.213 0.136 0.13 −0.012 0.039 0.127
0.005 0.014 0.125 0.135 0.887 0.659 0.145
131 132 128 133 132 133 133
DA/HVA ROC 0.116 0.156 0.12 −0.1 0.189 0.044 0.041
0.189 0.073 0.176 0.251 0.03 0.616 0.642
131 132 128 133 132 133 133
High NA ROC 0.223 0.197 0.35 0.028 0.13 0.136 0.104
0.01 0.023 0 0.746 0.137 0.118 0.232
131 132 128 133 132 133 133
NA/NHMA ROC 0.162 0.106 0.26 0.079 0.125 0.088 0.034
0.067 0.233 0.003 0.373 0.158 0.322 0.703
128 129 125 130 129 130 130
High AD ROC 0.125 0.19 0.237 0.012 0.041 0.05 0.124
0.156 0.029 0.007 0.894 0.644 0.57 0.156
131 132 128 133 132 133 133
AD/MHMA ROC 0.075 0.199 0.21 −0.06 0.046 0.001 0.009
0.403 0.024 0.019 0.501 0.608 0.99 0.922
128 129 125 130 129 130 130
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MHMA and AD/MHMA represent the activity of the MAO 
enzyme in this study. This enzyme metabolizes NA and 
AD to MHMA. The close correlative relationship between 
caseness for functional psychosis and elevated NA/MHMA 
and AD/MHMA levels were confirmed on ROC biomarker 
analysis and again on SEM analysis, where robust inverse 
z coefficient s were found between FMN–FAD and NA/
MHMA and FMN–FAD and AD/MHMA. Taken together, 
this means that: in a setting of low riboflavin availability 
MAO activity is low, leading to conserved, catecholamine 
elevation. Such MAO inhibition may relate more to -type 
B than type A form of the enzyme, since, in the periphery 
(from where urine samples for NA and AD are derived); 
these catecholamines are solely metabolized by the type B 
MAO enzyme. By contrast, DA may be metabolized by either 
type A or B form of MAO, possibly explaining why NA and 
AD elevations predominate over elevated DA findings in 
this study. Another explanation for the predominance of 
NA in this study, may also relate to animal study reports of 
intraluminal gastrointestinal bacteria, such as Escherichia 
coli, being a source of NA catecholamine (39). This imputed 
finding of FMN–FAD deficiency in relationship to MAO 
(40) and associated elevated catecholamines concur with 
multiple previous literature reports of riboflavin deficiency 
and MAO inhibition in behavior disorders, schizophrenia 
and schizoaffective disorder (12, 41–43).
TaBle 4 | Total sample correlation matrix for biochemistry variables and rOcs in relationship to each other.
rOc biochemistry variable correlates low  
VitD rOc 
aUc = 0.65
low rc 
folate rOc 
aUc = 0.654
low  
B6 rOc 
aUc = 0.638
high se B12 rOc 
aUc = 0.565  
(sig 80%)
high Free 
cu:Zn × 100 rOc 
aUc = 0.611
MThFr 
homozygous
high  
hisT rOc 
aUc = 0.576
pl HCY ROC 
AUC = 0.557  
(Sig 75%)
Correlation coefficient 0.13 0.179 0.063 −0.051 −0.045 −0.002 −0.036
Sig. (two-tailed) 0.138 0.039 0.481 0.558 0.605 0.986 0.677
N 132 133 129 134 133 134 134
Low VitD ROC 
AUC = 0.65
Correlation coefficient 1 0.239 0.055 −0.012 −0.038 −0.096 0.129
Sig. (two-tailed) 0.006 0.54 0.894 0.669 0.275 0.141
N 132 131 127 132 131 132 132
MTHFR_homozygous Correlation coefficient −0.096 −0.004 0.028 0.062 −0.107 1 −0.02
Sig. (two-tailed) 0.275 0.967 0.753 0.473 0.22 0.823
N 132 133 129 134 133 134 134
High HIST ROC Correlation coefficient 0.129 0.029 −0.116 0.153 −0.054 −0.02 1
Sig. (two-tailed) 0.141 0.738 0.191 0.077 0.534 0.823
N 132 133 129 134 133 134 134
Low RC folate ROC 0.239 1 0.262 −0.029 0.011 −0.004 0.029
0.006 0.003 0.741 0.899 0.967 0.738
131 133 128 133 132 133 133
High Se B12 ROC (Sig 80%) −0.012 −0.029 −0.26 1 −0.061 0.062 0.153
0.894 0.741 0.003 0.486 0.473 0.077
132 133 129 134 133 134 134
Low B6 ROC 0.055 0.262 1 −0.26 0.171 0.028 −0.116
0.54 0.003 0.003 0.053 0.753 0.191
127 128 129 129 129 129 129
High Free Cu:Zn × 100 ROC −0.038 0.011 0.171 −0.061 1 −0.107 −0.054
0.669 0.899 0.053 0.486 0.22 0.534
131 132 129 133 133 133 133
Symptom 
Intensity 
(SIR) 
Duration of
Illness (yrs)
Psychosis
Case-ness
FMN-FAD Red cell Folate Histamine
Serum vitamin B12
Plasma homocysteine
Free Cu/Zn
ZnCeruloplasmin
NA/MHMA AD/MHMA
Activated 
Vitamin D
Activated 
vitamin 
B6
HPL/
Creatinine
NA AD
FigUre 2 | Variables examined by seM analysis in the context of their relationship within the biochemical pathways of interest.
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TaBle 5 | structural equation model (seM) for 134 variable of interest and biochemistry including FaD as a putative marker. 
(Continued)
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TaBle 5 | continued 
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Total Sample Correlation and SEM Analysis Results 
Imply FAD Insufficiency Linked to Low Vitamin D
 – Low vitamin D levels yielded a sufficiently strong AUC to be 
included in the nutritional biochemistry bracket of biomark-
ers as a biomarker for functional psychosis (S6)
 – Psychosis caseness correlated highly with vitamin D levels.
 – Vitamin D levels correlated highly with all functional rat-
ings for disability, caseness, and symptom intensity (SIR) 
(Table 1).
 – Vitamin D levels inversely correlated with both NA and AD 
levels and their MAO metabolism markers NA/MHMA and 
AD/MHMA in a context where
 – NA/MHMA and AD/MHMA both demonstrated significant 
inverse correlates with vitamin D (and also with folate and 
activated B6) (Table 2), in a setting where
 – Vitamin D levels correlated positively with levels for vitamin 
B6 and folate.
In this study, vitamin D held significant correlates with 
respect to caseness, severity, and disability. Following on from 
vitamin D synthesis, FAD is required as a cofactor for vitamin 
D conversions to its active metabolic form of 25 (OH) vitamin 
D (44), which was the form of vitamin D assayed in this project. 
Furthermore, vitamin D levels and its ROCs indicating lower 
levels of vitamin D in cases than controls, correlated most 
closely with biomarker domains for impaired visual dysfunction 
and auditory dysfunction in psychosis (Table 4), both of which 
also held high correlates for disability and severity measures in 
the psychosis condition (Table 2). Vitamin D levels relate with 
greater inverse strength to elevated catecholamines (NA and AD) 
TaBle 6 | Key enzymes utilizing FMn or FaD in the biochemistry of schizophrenia or schizoaffective psychosis.
FMn- or FaD-dependent enzymes role reference
Methyl tetrahydrofolate reductase (MTHFR) Rate-limiting enzyme of the methylation cycle encoded by the MTHFR gene. Produces 5 methyl 
tetrahydrofolate (5MTHF) required to complete a turn of the folate cycle and allow methyl groups 
to enter the methionine cycle and homocysteine to be metabolized to Methionine. 
(18)
Monoamine oxidase (MAO) Utilized FAD as cofactor in first step metabolism of DA, NA, and AD. In this process, NA and AD 
are metabolized to MHMA
(19)
Diamine oxidase (DAO) (histaminease) Metabolism of histamine contains FAD and Cu moieties. Found in the digestive tract, placenta, 
and secreted by eosinophils
(20)
Glutathione reductase (GSSH reductase) (6) Thought 
related to flavin reductase and ferrodoxin reductase 
enzymes (see below)
Restores glutathione (GSH) to its active, reduced form, afte the its metabolism to oxidized 
Glutathione (GSSH) by glutathione peroxidase. GSH serves as a major contributor to the redox 
balance in cells through its ability to scavenge and reduce reactive oxygen species (ROS)
(21)
Methyl synthase reductase (MSR) works in tandem 
with Methionine synthase (MS)
MSR reduces B12 back to its activated form (from II to I form) after use by methyl synthase (MS) 
enzyme which metabolizes homocysteine to methionine. In most tissues, this provides the sole 
pathway for homocysteine remethylation; therefore, MTHFR deficiency from MTHFR 677TT is 
associated with high plasma concentrations of homocysteine. Substrates for the MS enzyme are 
methionine synthase-cob(II)alamin, NADPH, H+, and S-adenosyl-l-methionine. And its products 
are methionine synthase-methylcobalamin, S-adenosylhomocysteine, and NADP
(22, 23)
Pyridoxal kinase (PdxK) Pyridoxal phosphate is the active form of vitamin B6. Pyridoxal kinase is required for the 
synthesis of pyridoxal-5-phosphate from vitamin B6, and catalyzes the conversion of pyridoxal to 
pyridoxal 5′-phosphate in the presence of ATP
(24)
Betaine homocysteine methyl transferase (BHMT) Betaine = ttrimethyl glycine TMG). TMG degradation is a methylating pathway for methionine 
reconstitution utilizing homocysteine to produce dimethyl glycine (DMG) and methionine. DMG 
requires FAD to then de-methylates itself using mitochondrial dimethylglycine dehydrogenase 
(DMGDH). If FAD is deficient, DMG cannot de-methylate and the BHMT betaine degradation 
pathway is stalled.
(25, 26)
Flavin reductases (FR) (FMN–FAD reductase) Also 
called methemoglobin reductase. Has overlap function 
with 25 OH hydroxylase of vitamin D, Ferric reductase, 
and Biliverdin reductase b (see below). Also reduces 
the non-heme ferric center of ribonucleotide reductase 
and thereby influences DNA synthesis
Cytosolic enzymes that catalyze the reduction of FMN, FAD while allowing them to funnel 
electrons one at a time from NADH/NADPH to the ferrodoxin (Fe2+–S2+ protein) center of heme 
(with electron flow from NADPH to FAD to FMN to heme). In human erythrocytes. FR has high 
affinity for tetrapyrrole protoheme binding and reducing the iron center of methemoglobin. It also 
requires free flavins to catalyze the reduction of iron in order to release iron from storage or ferritin
(27, 28)
Biliverdin Reductase (Bilirubin-IXb reductase- isomer 
in erythrocytes)
Low B2, low B6, and low zinc combine to inhibit protoheme synthesis and B12 is also an inhibitor 
of Flavin reductase and FMN. Protoheme binds tightly to Bilirubin (Flavin) reductase to produce 
Biliverdin which in red calls is thought to be degraded by bilirubin IX reductase IXb to HPL. Where 
B2, B6, and zinc are low, protoheme synthesis is expected to be impaired and ALA is high
(29)
l-tryptophan pyrrolase [tryptophan 2,3-dioxygenase 
(TDO)]
A Heme flavoprotein cytosolic enzyme that catalyzes the first rate-limiting step of the kynurenic 
pathway- oxidative decarboxylation of L tryptophan with pyrrole ring cleavage, to produce 
NH3+CO2+ an unstable quinoxaline derivative that undergoes oxidative reduction with 
modification to resemble an HPL-like molecule. In a pseudomonas bacterium, the enzyme 
activity appeared to increase immediately after cessation of cell growth, responsible for anxiety-
related behavior. TDO knockout mice had increased plasma levels of tryptophan, serotonin, and 
5-HIAA in the midbrain and hippocampus
(30, 31)
Ferric reductase (FeR) Function also performed 
by heme c-type cytochromes in the membrane or 
periplasmic space (see below)
Iron can only be stored in ferritin in the ferric (Fe3+) state. FeR’s role is to deliver an adequate 
amount of safe ferric iron to the cells and may be an evolutionary adaptation to prevent toxic 
ferrous (Fe2+) leading to the Fenton reaction. FeR can transfer electrons from formate and 
FMN or FAD to form Fe+++ and Mn++++. Iron can only be stored in ferritin and transported 
by transferrin in the ferric (Fe3+) state. Ceruloplasmin also functions as a major ferroxidase in 
the blood, to hedge against any free iron in the circulation by converting iron to its ferric state 
that can be bound to transferrin. As such, it is majorly responsible for iron efflux from tissues, so 
when FAD is plentiful for FR function, ceruloplasmin is utilized in iron transport
(33–35)
25-OH-vitamin D3 hydroxylase Mitochondrial flavoprotein monooxygenase contains cytochrome P 450 heme component 
and an iron sulfur ferredoxin protein. In a three component monooxygenase enzyme system, it 
regulates vitamin D3 activation using flavin-dependent ferrodoxin reductase and adrenodoxin 
reductase. Production of Vitamin D3 is feedback regulated by parathyroid hormone. 1-25 OH D3 
necessary for full inflammatory response in macrophages. Is a mixed function oxidase, similar to 
adrenal cortex mono-oxygenases (ferredoxin type protein adrenodoxin and adrenoxin NADP+ 
reductase), concerned with steroidogenesis and with and P450-dependent monooxygenases
(36, 37)
P450 monooxygenases (P450 CYP4A4 responsible 
for 50% drug metabolism)
Flavin-dependent heme protein enzyme P450 monooxygenase enzymes require their heme iron 
to receive electrons from a flavin redox partner. Flavin electrons are transferred to the substrate, 
binding it. Once the substrate is bound, Fe within the heme (pyrrole) molecule is reduced.
(38)
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TaBle 7 | MThFr 677 split-sample correlates for psychosis caseness and functional measures, at 95% ci.
homozygous  
MThFr 
polymorphism
Biochemical parameter N rho P Wild-type enzyme 
(no MThFr gene 
polymorphism)
Biochemical parameter N rho P
Psychosis caseness HPL/creat 7 0.720 0.067 Psychosis caseness NA 65 0.634 0
Free 7 0.841 0.018 HIAA 65 0.475 0
Cu/Zn HPL/creat 65 0.33 0.007
No HIAA Vitamin B6 63 −0.335 0.007
RC folate 64 −0.245 0.051
Vitamin D 64 −0.245 0.005
Duration of Illness High DA ROC 7 0.068 0.081 Duration of illness NA 60 0.661 0
HPL/creat 7 0.808 0.028 HIAA 65 0.403 0.001
No HIAA HPL/Creat 60 0.306 0.017
Vitamin B6 58 −0.368 0.004
Symptom Intensity  
Rating (SIR)
DA 7 0.749 0.053 Symptom Intensity 
Rating (SIR)
DA 65 0.3 0.015
HPL/creat 7 0.768 0.044 NA 65 0.498 0
Free Cu/Zn 7 0.729 0.063 AD 65 0.508 0
High Free Cu/Zn ROC 7 0.676 0.096 HIAA 65 0.403 0.001
Low histamine <0.035 μg/l 7 0.676 0.096 HPL/Creat 65 0.341 0.005
No HIAA Vitamin D 64 −0.288 0.021
Low RC folate ROC 64 0.217 0.086
Clinical Global Illness 
severity (CGI)
High DA ROC 7 0.794 0.033 Clinical Global Illness 
severity (CGI)
NA 58 0.596 0
DA 7 0.896 0.006 HIAA 58 0.509 0
Free Cu/Zn 7 0.717 0.07 HPL/creat 58 0.223 0.092
No HIAA RC folate 57 −0.344 0
Vitamin B6 56 −0.359 0.007
Vitamin D 57 −0.255 0.055
Global Assessment of 
Function (GAF)
Free Cu/Zn 7 −0.741 0.057 Global Assessment of 
Function (GAF)
NA 58 −0.522 0
No HIAA HIAA 58 −0.483 0
HPL/creat 58 −0.297 0.024
Vitamin B6 56 0.273 0.042
Vitamin D 57 0.297 0.025
Social and 
Occupational 
Assessment Scale 
(SOFAS)
Nil Social and 
Occupational 
Assessment Scale 
(SOFAS)
DA 58 −0.283 0.031
NO HIAA NA 58 −0.593 0
RC folate 58 −0.287 0.029
HPL/creat 58 −0.261 0.048
Vitamin D6 56 0.364 0.006
Vitamin D 57 0.255 0.055
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than to their metabolic ratios (NA/MHMA and AD/MHMA), 
which fits an alternative hypothesis that elevated catecholamines 
directly invoke cyclic adenosine monophosphate (cAMP) gene 
expression and cAMP induction of parathyroid hormone (45). 
The role of parathyroid hormone has been implicated in schizo-
phrenia (46) and it releases calcium from cells that must then 
be replaced by the action of vitamin D. Such a situation may, 
therefore, result in overutilization of vitamin D with osteoporosis 
as also reported in the schizophrenic condition (47).
Total Sample Correlation and SEM Analysis Results 
Imply FAD Insufficiency and Low Folate
 – The folate marker in this study yielded a sufficiently strong 
AUC to indicate that low levels of folate is a biomarker for 
functional psychosis (S6).
 – Psychosis caseness correlated highly with the folate ROC vari-
ables (Table 3)
 – Red cell folate level and its ROC correlated with all dis-
ability functions, caseness, and symptom intensity measures 
(Tables 2 and 3).
 – Folate levels inversely correlated with both NA and AD levels 
and their MAO metabolism markers NA/MHMA and AD/
MHMA in a context where
 – NA/MHMA and AD/MHMA levels both demonstrated 
significant inverse correlates with folate levels (Table 2)
 – Low folate ROCs correlated most closely plasma with low HCY 
and low vitamin D ROCs (Table 3) and folate and vitamin D 
levels were significantly correlated.
 – On SEM analysis, FMN–FAD levels and red cell folate lev-
els were significantly linked (n =  134, z =  2.46, P =  0.014) 
(Table 6).
 – Folate levels correlated positively with vitamin D and vita-
min B6 levels all of which formed deficit biomarkers in this 
study.
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 – Given the flow-on effect of low folate and 5MTHF on the 
methylation cycle, there was an expected strong cor-
relative link between total low folate levels and HCY levels 
(Table 2) (48).
Apart from low folate absorption levels related to riboflavin-
deficiency-induced gut inflammation (49), riboflavin is required 
for biosynthesis of folate coenzymes without which lower levels of 
useful folate are found in animal studies (50). In this study, major 
folate derivatives were assayed in the folate test, so inhibition 
of the MTHFR enzyme by insufficient FAD coenzyme was 
included in the inability of this enzyme to provide sufficient 
5MTHF (51,  52). This would further explain the relationship 
found between FAD and red cell folate on SEM analysis.
Total Sample Correlation and SEM Analysis Results 
Imply FMN Insufficiency Linked with  
Low Activated B6
 – Low B6 levels yielded a sufficiently strong AUC to be included 
as a biomarker for functional psychosis (S6) and psychosis 
caseness correlated highly with vitamin B6 ROC (Table 3).
 – The low B6 ROC correlates highly with all disability functions 
and symptom intensity measures (SIR) (Tables 2 and 3).
 – B6 ROC correlate marginally with Free Cu/Zn ROC (n = 129, 
rho = 0.171, P = 0.053)
 – On SEM analysis, a positive coefficient was found between 
FAD and activated B6 (n = 134, z = 2.25, P = 0.025), with
 – a significant negative relationship found between activated B6 
and plasma HCY (n = 134, z = −2.37, P = 0.018) in a setting 
where B6 levels correlate inversely with serum B12 (n = 129, 
rho = −0.260, P = 0.009) (Table 2) and low vitamin B6 ROC 
correlates closely with high serum B12 ROC (Table 3).
 – B6 levels and held significant inverse correlates with all 
catecholamine parameters and the low vitamin B6 ROC cor-
related significantly with NA and AD, but not with DA.
Pyridoxine 5′-phosphate oxidase is a FMN-dependent 
enzyme that converts vitamin B6 into its activated form -pyri-
doxine 5 phosphate (PLP), as was assayed in this study (53). In 
FMN insufficiency, activation of B6 is impaired (24); therefore, 
S-adenosylhomocysteine-hydrolase (SAHH) activation within the 
methylation cycle is retarded and S-adenosyl homocysteine (SAH) 
is conserved. Catecholamine metabolism by COMT activity is 
inhibited by high SAH (54) leading to conserved and elevated cat-
echolamines. Within the catecholamine synthesis pathway, DOPA 
decarboxylase also requires activated B6 as a necessary cofactor for 
DA synthesis. If B6 activation is retarded by insufficient FAD, DA 
synthesis is also retarded, which explains the absence of correlates 
between high DA ROC and Low B6 ROC in a setting where there 
is overall COMT catecholamine conservation. Vitamin B6 is a 
necessary cofactor for several enzymes within the transulfuration 
pathway to glutathione synthesis. Its inactivity through insufficient 
FMN will also retard HCY metabolism to cysteine and so elevate 
HCY levels as well as contributing to reduced glutathione (GSH) 
production and oxidative stress. Given the relationship of B6 to this 
pathway and its participation in the heme synthesis pathway (55, 
56), it was interesting that there was a notable lack of significant 
correlates found between vitamin B6 and the supposed oxidative 
stress and heme-degredation marker, HPL. This can perhaps be 
explained by the relationship found between the vitamin B6 and 
Free Cu/Zn ROCs, which implies that when unbound copper is 
elevated, vitamin B6 is also elevated. A possible explanation for 
this finding again directs attention to the transulfuration pathway 
where Cu inhibits the rate-limiting enzyme cystathione beta 
synthase (CBS) (57), leading to underutilization of vitamin B6, 
which is a necessary cofactor for at least four enzymes within this 
pathway (10).
Total Sample Correlation and SEM Analysis Results 
for Elevated Histamine
 – High histamine ROC (n = 134, rho = 0.1641, P = 0.058) cor-
related with psychosis caseness in this study and
 – NA+ histamine together form a high quality ROC (n = 134, 
rho = 0.839, P = 0.0001).
 – However, no correlation strength was found between NA/
MHMA ROC or AD/MHMA ROCs and high histamine ROC 
(Table 3), but
 – a marginally significant negative relationship was found 
between histamine and free Cu/Zn (n =  134, rho = −1.95, 
P = 0.052) that was supported on SEM analysis by a negative 
coefficient between these two variables (n = 134, z = −1.95, 
P = 0.052).
Histamine is a neurotransmitter that creates wake-fullness and 
plays a role in local immune response. Histamine emerged as a 
low-grade biomarker in this study and together with NA, formed 
a very strong compound biomarker for functional psychosis with 
symptom correlates linked to anxiety, fear, and over-arousal in 
our patient sample (17). Inflammatory bowel disease releases 
histamine from mast cells in the gut lining, a hypothesis that is 
supported within the immune activation theory of schizophrenia 
(58, 59). SEM analysis demonstrated a negative relationship 
between histamine and free Cu/Zn, which will be discussed 
later in terms of low histamine findings. Though FAD did not 
directly relate to histamine on SEM analysis, insufficient FAD 
for good MTHFR activity may provide one explanation since 
undermethylating environments with insufficient SAMe avail-
able for the histamine-metabolizing enzyme N methyl histamine 
means that there is a tendency for histamine to be conserved and 
elevated (60).
Total Sample Correlation and SEM Analysis  
Results for HPL
 – elevated HPL ROC and NA/MHMA (n = 133, rho = 0.205, 
P = 0.018).
 – elevated HPL ROC and AD/MHMA (n = 130, rho = 0.224, 
P = 0.010).
 – HPL levels and vitamin B12 levels both correlated with the 
symptom intensity index (SIR) (Tables 2 and 3) (17).
 – HPL/creatinine has an inverse relationship with the MTHFR 
homozygous 677TT polymorphism (n = 133, rho = −0.181, 
P = 0.037).
 – SEM analysis found no significant relationship between HPL 
and FMN–FAD.
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The oxidative stress marker in this study, heme-hydroxyl 
pyrroline-2-one (HPL), has been reported in the urine of persons 
suffering from schizophrenic psychosis (4). In this study, signifi-
cant correlates were found between NA/MHMA and AD/MHMA 
and elevated HPL/creatinine levels in a setting where high HPL 
levels formed a biomarker for functional psychosis and held high 
correlation with psychosis symptom intensity index (SIR) (17). 
The closest correlative relationship for HPL was an inverse one 
with the MTHFR homozygous polymorphism, the significance 
of which is discussed in the next section.
Glutathione reductase is a FAD-dependent enzyme, which 
is sensitive to riboflavin deficiency (61). This enzyme lies at 
the bottom of the transulfuration pathway and requires FAD 
cofactor for the utilized, oxidized form of glutathione (GSSH) 
to re-constitute itself back to its reduced active (GSH) form in 
order to be useful in antioxidant defense (Figure 1) (62). In the 
absence of synthesis of GSH in the transulfuration pathway, the 
effects of heme-oxygenase in the first step toward heme synthesis 
would be expected to lead to increased downstream porphyrin 
synthesis and heme formation. However, other enzymes in 
this heme- synthesizing pathway, such as the critical enzyme 
d-aminoaluvenicacid (ALA) synthase (63), are also retarded by 
insufficient activated B6. In such a setting, low heme produc-
tion and lower antioxidant bilirubin levels would be expected 
to lead to metabolic crisis and neuronal death (64), Amid such 
an oxidative-heme crisis, heme’s porphyrobilinogen side chain 
is perported to be decarboxylated and deaminated to form a 
labile hydroxylactam hemopyrrole fragment that corresponds 
to the hydroxyhaemopyrroline-2-one (HPL) molecule that 
is a biomarker in this study (4). In such a low heme synthesis 
context, it is possible that heme components within multiple 
heme-flavo-enzymes, such as tryptophan pyrrolase [tryptophan 
2, 3-dioxygenase (TDO)] and P450 monooxygenase enzymes, 
may also be degraded to form HPL (Table  6). Since linear 
tetrapyrroles, such as bilirubin, play a significant role as antioxi-
dant and anti-inflammatory agents, the reduction of protoheme 
synthesis by B6 unavailabilty and its further degradation to bili-
rubin allows further vulnerability to inflammation and oxidative 
stress. Oxidative damage to cells is in turn accompanied by kinin 
release precipitating an inflammatory acute phase reaction with 
elevated acute phase reactants, such as ceruloplasmin (Cp) and 
increased bound copper. In such a case, free (unbound) copper 
may be insufficiently available for DAO and MAO activity (65, 
66) and for DA carboxylase conversion of DA to NA (67). This 
will respectively predispose to elevated histamine, elevated cat-
echolamine and conserved DA, to produce the kind of high DA, 
elevated neurotransmitter profile that accompanies hyperactive, 
manic symptoms (17, 68) (Figure 3).
sUMMarY anD DiscUssiOn OF 
FinDings FOr cOrrelaTiOn anD  
seM analYsis OF The FUll saMPle
In this study, intra-class correlative variables for catecholamines 
were found to conform to known relationships for their estab-
lished pathways for synthesis and metabolism. Furthermore, 
catecholamine/metabolite ratios indicating abnormal  mono-
amine oxidase activity, could not be explained without imputing 
riboflavin-related compounds, such as FMN and FAD as inter-
mediary variables. SEM analysis then  confirmed that riboflavin-
derived FMN–FAD played a 71% role in connecting variables 
within the biochemical pathways of interest. In this study, low 
folate and low activated vitamin B6 levels were also found related 
to both caseness and disability measures for functional psychosis 
(Tables 2 and 3), and SEM analysis confirmed their significance, 
and relatedness to FMN-FAD, by finding significant positive z 
coefficients between FMN–FAD and red cell folate and FMN–
FAD and activated B6.
Riboflavin (vitamin B2) is a water-soluble vitamin derived 
from whole grains, wheat germ, wild rice, mushrooms, soybeans, 
brewer’s yeast, milk, yogurt, eggs, broccoli, Brussels sprouts, and 
spinach. Riboflavin serves as the precursor of FMN, which is 
the further precursor of FAD (69). In a riboflavin kinase reac-
tion regulated by thyroid hormone (Figure 1) (70), riboflavin is 
transformed to FMN by the phosphorylation and FAD is then 
formed by the action of a second enzyme, FAD synthase. In 
riboflavin deficiency, plasma concentrations of FMN and FAD 
are, therefore, lowered (71, 72).
Stress is both a risk factor and inherent component of 
schizophrenia (73, 74) and it is well-known that the chaotic 
lifestyle accompanying psychosis is associated with stress and 
poor dietary vitamin intake. Low riboflavin related to poor diet 
in schizophrenia (75) may enhance susceptibility to low grade 
bowel inflammation and poor vitamin absorption (76) In addi-
tion, chronic stress with high cortisol levels has been found to 
reduce intestinal absorption of riboflavin (77). Moreover, ribofla-
vin deficiency is reported associated with impaired maintenance 
of mucous membranes and low grade bowel inflammation (78, 
79) which could well contribute to the malabsorption of nutri-
ents such as B6, zinc, and folate (80). In this regard, individuals 
with schizophrenia have reported gastrointestinal problems and 
inflammation markers (81, 82), in a setting where diet changes and 
dysregulation of gut flora has also been associated with immune 
and inflammatory conditions (83). Moreover, in animal studies, 
riboflavin supplementation has been demonstrated to improve 
zinc absorption (84) and a marker of abnormal gut mucosal 
integrity has been reported linked to elevated HPL levels (85). 
This result could indeed be expected if subclinical riboflavin-
deficiency from poor diet or disturbed gut microbiome, renders 
the gut mucosal wall unable to maintain its surface mucosal 
integrity, resulting in the kind of gastrointestinal inflammation 
and immune activation that has been reported in schizophrenia. 
For these reasons, riboflavin may occupy a critical position in the 
link between high schizophrenia rates, immune activation with 
inflammation in famine conditions, where grains and meat are 
difficult to procure (86).
Flavin adenine nucleotide is a necessary cofactor for activ-
ity of the MTHFR enzyme that manufactures 5-MTHF methyl 
groups for running the methylation cycle. When the MTHFR 
667 C →  T gene encoding this enzyme is in a homozygous 
(MTHFR 677TT) state (where thymidine fully replaces its 
cytosine residues at position 677 of the gene), the encoded 
enzyme encoded has impaired ability to manufacture sufficient 
FigUre 3 | summary outcome when there is no MThFr Polymorphism governing activity of the MThFr enzyme, and where folate, vitamins,  
and flavins are low. Where correlation significance index [SI] = [(1 – P-value) × 1000], caseness for schizophrenia or schizoaffective disorder relates to NA 
[SI = 100] and HPL/Creatinine [SI = 93], in a setting where catecholamines held significant correlates with the wild-type enzyme and where NA relates to SIR 
[SI = 100], GSI [SI = 100], DOI [SI = 100], and NA relates to NA/MHMA [SI = 100]. With respect to vitamin levels, Low Vitamin B6 relates to SOFAS [SI = 94], CGI 
[SI = 93], and DOI [SI = 86]. Low vitamin D relates to SIR [SI = 79], CGI [SI = 59], SOFAS [SI = 45], and low folate levels relate to Psychosis Caseness [SI = 49]. All 
catecholamines formed highly significant positive correlates with HPL. All catecholamines held significant inverse correlates with folate, vitamin B6 and vitamin D. 
Free copper to zinc ratio formed no correlates of significance within this data-set. Within the data set, homocysteine held significant inverse correlates with folate 
and vitamin B6. UnDer-MeThYlaTiOn DiMensiOn characTerisTics. high oxidative stress levels. high catecholamine levels, where elevated 
Da and na predominate. lOW vitamin B6, D and folate levels. lOW unbound cu levels with tendency to high Da. Tendency to higher histamine and 
higher 5 hiaa excretion.
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5 MTHF to supply the methylation cycle. 5MTHF participates 
in MS conversion of HCY back to methionine and subsequent 
production of the methyl donor SAMe. Within the MS reac-
tion, FMN is also required for the conversion of cobalamin 
cofactor to its active form. Though most tissues prefer to 
utilize the MS HCY to methionine conversion pathway, an 
alternative HCY metabolism rescue pathway exists for use 
when MS activity is blocked by insufficient 5MTHF and FMN 
cofactors. In this alternative pathway, betaine degradation is 
initiated via betaine homocysteine methyltransferase (BHMT) 
(Figure  1); however, this enzyme may be retarded in Flavin 
insufficient states due to the fact that the second step in its 
pathway requires FAD for dimethyl glycine (DMG) HCY de-
methylation and without sufficient FAD, DMG accumulates 
and the BHMT betaine degradation pathway is stalled (26, 87). 
Both vitamin D and vitamin B6 also require FMN or FAD for 
synthesis into their activated forms, as assayed in this study 
(24, 88) and the active (reduced) form of glutathione (GSH) 
also requires FAD as a cofactor (21). FMN–FAD-dependent 
enzymes are also required for MAO activity in metabolizing 
the first step of catecholamine metabolism and diamine oxi-
dase (DAO) requires FMN for metabolism of histamine (19, 
20). Other enzymes requiring flavin as cofactors or as internal 
moieties to assist their activity are ubiquitous in body and 
brain biochemistry. Many have mixed functions, as outlined in 
Table 6. Understanding the meaning of the results of this study 
should, therefore, be undertaken in conjunction with Table 6, 
and Figures 1, 3 and 4 which further display the potential role 
of Riboflavin, FMN, and FAD in the biochemistry of functional 
psychosis.
FigUre 4 | summary outcome when there is a homozygous 677TT polymorphism governing low activity of the MThFr enzyme, but where folate and 
flavin availability in the presence of normal hormonal conditions and sufficient sources of flavins and folate from dietary and gastrointestinal 
sources. Where significance index [SI] = [(1 − P-value) × 1000], caseness for psychosis is only marginally related to HPL/Creatinine [SI = 33]. Caseness was also 
marginally related to Free Cu/Zn ratio [SI = 33], where Free Cu/Zn also relates to GAF [SI = 43] and CGI [SI = 30]. Catecholamine held no significant correlates 
within this data set. Levels of folate are low in relationship to high homocysteine [SI = 84], and B12 [SI = 45] and high homocysteine levels correlate with low B6 
levels [SI = 14]. There is no inference in the correlates to suggest that vitamin D levels are low. Flavin sufficiency is implied. Less severe oxidative stress severity and 
disability compared to the wild-type enzyme. High Cu levels promote DA metabolism to NA, with tendency to lower DA than NA levels. Vitamin levels are normal or 
increased. Tendency to lower histamine and no 5HIAA excretion. risK OF OVer-MeThYlaTiOn exisTs.
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homozygous types) and to examine key correlates within those 
three data sets. Though there were only seven participants in the 
study with the homozygous form of the 667TT gene, comparison 
of the data sets still yielded variables of significance and correla-
tive results analysis are presented in Tables 7 and 8 with results 
summarized in Figures 3 and 4.
split Data-set results for Wild-Type 
MThFr enzyme
For the sake of emphasis, significant correlates for between 63 and 
65 variables in this part of the split data set (Table 8) were indexed 
for their level of significance using the formula Significance Index 
[SI] =  [(1 −  P-value) ×  1000] with the following significance 
indices obtained:
Caseness for schizophrenia or schizoaffective disorder 
relates to NA [SI = 100] and HPL/Creatinine [SI = 93], 
in a setting where catecholamines held significant corre-
lates with the wild-type enzyme and where NA relates to 
SIR [SI = 100], GSI [SI = 93] and DOI [SI = 93] and NA 
investigation of MThFr 677TT gene 
status in relationship to Key Variables 
Using a split Data set
The MTHFR gene was selected as a marker for examination in 
this study because this gene codes for the MTHFR enzyme which 
is the rate-limiting factor in the methylation cycle (18). In the 
normal form of this gene, cytosine is at position 677, leading to 
an alanine at amino acid 222. However when there is thymidine at 
position 677, there is a valine substitution at amino acid 222 and 
this homozygous form of the gene (677TT) encodes a thermolabile 
enzyme with reduced activity compared to individuals with the 
CC or CT (heterozygous) forms of the gene (89). Though there is 
ethnic variability related to this polymorphism, 10% of the North 
American population are T-homozygous for this polymorphism.
The MTHFR gene polymorphism has a reported relationship to 
schizophrenia (90) and the MTHFR enzyme coded by the 677TT 
gene loses its FAD cofactor three times faster than the wild-type 
protein (91). It was, therefore, decided to split the data set from 
this study into three data-sets based upon the three possible gene 
coded states of the MTHFR enzyme (wild type, heterozygous and 
TaBle 8 | continuedTaBle 8 | MThFr 667 split-sample correlates for psychosis biochemistry 
at 95% ci.
Biochemical 
correlate
N rho P
homozygous MThFr polymorphism
DA level NA 7 0.679 0.094
High DA ROC NA 7 0.791 0.034
DA/HVA level Nil sig
NA Level DA/HVA 7 0.786 0.036
High NA ROC NA 7 0.791 0.034
NA/MHMA DA/HVA 7 0.964 0
AD Level nil sig
High AD ROC nil sig
HPL/creat Caseness 7 0.722 0.067
SIR 7 0.768 0.044
DOI 7 0.808 0.028
RC folate Homocysteine 7 −0.739 0.058
Low red cell folate ROC Homocysteine 7 0.874 0.01
Homocysteine RC folate 7 −0.739 0.016
Vit B6 7 −0.847 0.016
Vitamin B6 Homocysteine 7 −0.847 0.016
Low B6 ROC Homocysteine 7 0.798 0.032
Serum B12 HPL/creat 7 0.679 0.094
Vit D level Se Cp 7 0.771 0.042
Low Vit D RC zinc 7 −0.964 0
ROC Nil
Free Cu/Zn Caseness 7 0.722 0.067
GAF 7 −0.741 0.057
Cp Zinc 7 −0.716 0.07
Vitamin D 7 0.771 0.042
RC zinc Vitamin D 7 −0.964 0
Histamine ROC Vitamin B6 7 0.866 0.012
Wild-type enzyme (no MThFr gene polymorphism)
DA level DA/HVA 65 0.294 0.017
NA 65 0.483 0
HPL/creat 65 0.307 0.013
RC folate 64 −0.234 0.063
Vitamin B6 63 −0.257 0.042
Vitamin D 64 −0.307 0.002
High DA ROC DA/HVA 65 0.372 0.001
NA 65 0.399 0.006
HPL/creat 65 0.339 0.004
RC folate 64 −0.352 0.034
Vitamin D 64 −0.265 0.031
DA/HVA level RC folate 64 −0.27 0.08
Cp 65 0.219
NA Level Caseness 65 0.634 0
HPL/creat 65 −0.238 0.062
RC zinc 65 −0.247 0.047
Vitamin D 64 −0.477 0
High NA ROC HPL/creat 65 0.226 0.032
Vitamin B6 63 −0.383 0.002
RC zinc 65 −0.238 0.056
Vitamin D 64 −0.326 0.009
Biochemical 
correlate
N rho P
NA/MHMA NA 63 0.82 0
Vitamin B6 61 −0.227 0.078
RC zinc 63 −0.23 0.065
Vitamin D 64 −0.36 0.004
AD level NA 65 0.743 0
HPL/creat 65 −0.241 0.053
Vitamin D 64 −0.361 0.003
High AD ROC NA 65 0.69 0
Vitamin D 64 −0.345 0.005
HPL/creat Caseness 65 0.33 0.007
NA 65 0.233 0.062
Cp 65 0.262 0.035
RC zinc 65 −0.261 0.035
RC folate Caseness 64 −0.245 0.051
DA/HVA 64 −0.27 0.031
Homocystein 63 −0.26 0.036
Se B12 64 0.226 0.072
Vitamin B6 62 0.287 0.024
Vitamin D 63 0.295 0.019
Low red cell folate ROC Homocystein 63 0.283 0.025
Vitamin D 63 −0.016 0.018
Homocysteine RC folate 63 −0.264 0.036
Vitamin B6 NA 63 −0.384 0.002
RC folate 62 0.287 0.024
RC zinc 62 0.293 0.02
Low B6 ROC NA 63 0.45 0
Se B12 63 −0.233 0.021
RC folate 62 −0.233 0.068
RC zinc 63 −0.302 0.016
Vitamin D 62 −0.292 0.024
Serum B12 RC folate 64 0.226 0.072
Vitamin B6 63 0.235 0.063
High Se B12 ROC RC zinc 65 0.245 0.05
Vit D level NA 64 −0.447 0
RC folate 63 0.295 0.019
Low Vit D ROC NA 64 0.393 0.001
Se B12 64 −0.336 0.06
Vitamin B6 63 −0.314 0.013
RC zinc 64 −0.284 0.023
Free Cu/Zn Cp 64 −0.218 0.083
RC zinc 64 −0.325 0.009
Cp HPL/creat 65 0.262 0.035
DA/HPA 65 0.219 0.08
RC zinc HPL/creat 65 −0.261 0.035
B6 63 0.293 0.02
Free Cu/Zn 64 −0.325 0.009
Histamine ROC Free Cu/Zn 64 −0.212 0.093
(Continued)
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relates to NA/MHMA [SI = 93]. With respect to vita-
min levels, low vitamin B6 relates to SOFAS [SI = 94], 
CGI [SI = 55], DOI [SI = 86]. Low vitamin D relates 
to SIR [SI = 79], CGI [SI = 55], SOFAS [SI = 45], and 
Low folate levels relate to psychosis caseness [SI = 49]. 
All catecholamines formed highly significant positive 
correlates with the oxidative stress marker, HPL. All 
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catecholamines held significant inverse correlates 
with folate, vitamin B6 and vitamin D. Free Copper to 
zinc ratio formed no correlates of significance within 
this data-set. Within the data set, homocysteine held 
significant correlates with folate and vitamin B6.
Flavin adenine nucleotide is a necessary cofactor for vitamin 
D and vitamin B6 activation and the wild-type MTHFR enzyme 
is also sensitive to riboflavin status (24, 88, 92). In an unstable 
folate or FAD deprived setting, the amount of MTHFR’s product 
5-methylTHF is reduced relative to other folate forms. In turn, 
the downstream enzyme methionine sulfoxide reductase (MSR) 
(Figure 1) is deprived of its 5MTHF substrate, bringing about 
stasis of its conjointly acting enzyme MS. MS converts HCY back 
to methionine to replenish the methylation cycle. This set-back 
in HCY metabolism is also retarded in a low Flavin environment 
by the inability of vitamin B12 to reactivate itself after use and 
continue to cofactor MS (93) (Figure 3). In addition, there is a 
supplementary enzyme BHMT which in normal circumstances 
can rescue any MS retarded HCY metabolism blockage by its 
product, DMG utilizing FAD for re-methylation. In a low FAD 
environment,  this enzyme finds its DMG product increased and 
its activity inhibited (94). Such stasis in both MS and BHMT path-
ways within the methylation cycle results in reduced methionine 
reconstitution and reduced SAMe output (Figure 3). Then, the 
COMT enzyme which requires SAMe as a cofactor will be less 
able to metabolize catecholamines and elevated catecholamines 
will ensue. The net effect is that folate and methionine cycle 
stasis occurs creating an under-methylating state with reduced 
SAMe formation.
The direction of significant correlates obtained from the split 
data set for the wild-type MTHFR enzyme (Tables  8 and 9) 
are consistent with an under-methylating biochemistry profile 
within which FMN–FAD insufficiency explains the combined 
inter-relationships of elevated catecholamine levels, elevated 
oxidative stress (HPL) and low levels of folate, vitamin B6 and 
vitamin D. A significant correlate was also found for high Se B12 
ROC in relationship to zinc, though due to the fact that MSA 
for which B12 cofactors is a zinc utilizing enzyme (95). It was 
also considered significant that despite free copper to zinc ratio 
forming an elevated biomarker in the overall sample set, no 
significant variables were found related to it in the split data set 
for the wild-type enzyme. This implies that elevated free copper is 
not a significant issue requiring dynamic consideration when the 
wild-type enzyme is present in schizophrenia and schizoaffective 
psychosis.
Vitamin B6 is dependent upon FAD for its activation to pyri-
doxine 5 phosphate (PLP) and adequate levels of activated vita-
min B6 are required for both serotonin synthesis by l-tryptophan 
hydrolase and metabolism of serotonin’s precursor substrate 
l-tryptophan in the first part of the kynurenic pathway. Activated 
B6 and FAD are also required further down this pathway for 
breakdown of kynurenic acid (96–98). Therefore, in a no poly-
morphism MTHFR setting with low FAD and consequent low 
activated vitamin B6, metabolism in the kyneurenic pathway is 
inhibited and l-tryptophan might be expected to be preferentially 
diverted into the serotonin synthesis pathway. This may explain 
the significant levels of serotonin metabolite 5HIAA found in 
this study when there is no MTHFR polymorphism coding for 
activity of the MTHFR enzyme.
aligned Full sample, seM, and  
split sample results related to the 
homozygous MThFr 677TT 
Polymorphism
In this study, a full sample data-set was used to obtain a 
background understanding of dynamics at work between 
biochemical and functional variables. SEM analysis then 
confirmed that riboflavin-derived FMN–FAD played a 71% 
role in connecting variables within the biochemical pathways 
of interest. Given this understanding, the data set was split to 
examine the influence of the wild-type 677C → T, homozygous 
677TT, and heterozygous 677CT genes coding for the MTHFR 
enzyme, with respect to other biochemical variables of interest 
within the data-set. Dynamic understandings derived from 
these three different levels of data analysis were then collated 
and aligned in order obtain a broad perspective of the dynam-
ics at work within the biochemistry of schizophrenia and 
schizoaffective psychosis.
In the full participant sample (n =  134), the homozygous 
677TT MTHFR polymorphism had no significant ROC strength 
for differentiating cases from non-cases (n = 134, AUC = 0.537, 
P =  0.3577) (S7) and a non-significant negative correlate was 
found between caseness and this polymorphism (n  =  134, 
rho = −0.335, P = 0.700).
 – No correlative relationship was found between either elevated 
NA/MHMA or AD/MHMA ROCs and the homozygous 
677TT MTHFR polymorphism.
 – No significant correlation was found between the MTHFR 
homozygous polymorphism and any deficit of the vitamin 
markers for B6, vitamin D, or B12
 – As expected (due to reduced MTHFR polymorphism prod-
ucts and HCY metabolism impairment), there was a positive 
correlation between the MTHFR homozygous polymorphism 
and HCY levels (n = 134, rho = 0.224, P = 0.009).
 – There was an inverse correlate existing between the homozy-
gous form of MTHFR and the high HPL/Creatinine ROC 
oxidative stress biomarker (n = 133, rho = −0.181, P = 0.037). 
This means that very elevated HPL levels indicative of oxida-
tive stress are not associated with the homozygous MTHFR 
polymorphism.
 – In keeping with other studies, correlations were found 
between the homozygous 677TT polymorphism and HCY 
levels (99, 100).
For emphasis, P-values within the split sample for MTHFR 
677TT were again indexed for significance, using the formula 
Significance Index [SI] = [(1 − P-value) × 1000] and the follow-
ing indices were obtained:
 – Caseness for psychosis is only marginally related to HPL/
creatinine [SI = 33].
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 – Caseness was also marginally related to Free Cu/Zn ratio 
[SI = 33], where Free Cu/Zn also relates to GAF [SI = 43] and 
CGI [SI = 30].
 – Apart from expected inter-relationships between catechola-
mine entities themselves, as a whole they held no significant 
correlates within this data set.
 – Correlate directions also infer that vitamin levels of folate are 
low in relationship to high HCY [SI = 84], and B12 [SI = 45] 
and that high HCY levels correlate with low B6 levels [low B6 
ROC in relationship to HCY [SI = 14]].
 – There is no inference in the correlates to suggest that vitamin 
D levels are low unless there is a high zinc level, which is not 
a general finding associated with correlates for elevated free 
copper.
As judged by HPL significance levels, when the MTHFR 
enzyme is homozygously coded (677TT), oxidative stress is 
nowhere near as severe as for the folate/FAD depleted wild-type 
enzyme. Furthermore, catecholamines are less elevated in the 
677TT genotype. Elevated Cu/Zn ratios, though only marginally 
related to psychosis caseness in the 677TT genotype, nevertheless 
play a significant role in relationship to functional disability and 
severity of illness. This effect is probably due to coppers inhibi-
tion of CBS, promoting HCY elevation and halting glutathione 
synthesis (57). Unbound copper is a powerful oxidant causing 
inflammation and free radical damage to the tissues (101) so its 
relationship to caseness is not surprising.
For this reason correlative findings for elevated free Cu/Zn 
ratio were examined again in the whole sample data set, with the 
following findings:
 – High% free copper/zinc ratio ROC (n = 133, AUC = 0.611 
P = 0.022), but
 – free% cu/zn ratio correlates most closely with activated vita-
min B6 levels (n = 129, rho = 0.171, P = 0.053), and there is 
no demonstrated correlative relationship to levels of folate or 
other vitamins (Table 2).
 – as expected from the dynamics of ceruloplasmin and zinc bind-
ing with copper, an interesting marginal inverse SEM covariance 
was noted between ceruloplasmin (Cp) and caseness (n = 134, 
z  =  −1.87, P  =  0.062) and % free Cu/zinc ratio is equally 
inversely covariant with ceruloplasmin (Cp) (n = 134, z = −3.58, 
P = 0.000) and with plasma zinc (n = 134, z = −3.37, P = 0.001).
High% free Cu:Zinc ratio was a sufficiently significant finding 
in the overall data set to meet ROC criteria for biomarker status. 
The fact that copper is an inhibitor of the CBS enzyme that leads 
to glutathione synthesis (57, 101) and vitamin B6 is a cofactor for 
four enzymes related to this pathway, may explain why vitamin 
B6 is underutilized in the setting of high free copper and why 
HCY is also elevated in this setting. In the total sample data set 
and in the SEM findings, the relationship of correlates between % 
free copper, zinc, and ceruloplasmin nicely fitted the known rela-
tionship that exists between excess free copper and low zinc and/
or low ceruloplasmin levels (102). In an inflammatory setting, 
Cp is an acute phase reactant that can act as a diamine oxidase 
(ceruloplasminase) to enhance histamine metabolism and lower 
histamine levels (103). Elevated free copper, as found in this study, 
is also expected to support the activity of the copper containing 
enzyme diamine oxide (DAO), which also metabolizes histamine 
leading to lowered histamine levels (65, 104). In this regard, 
an interesting marginally significant negative relationship was 
found to exist between free Cu/Zn and histamine and (n = 134, 
rho = −1.95, P = 0.052) and this was confirmed by a marginal 
negative coefficient between these two variables on SEM analysis 
(n = 134, z = −1.95, P = 0.052). In this setting, NA/MHMA and 
AD/MHMA levels related inversely to low histamine (designated 
as <0.35 µg/l) (n = 130, rho = −0.199, P = 0.023), meaning that 
MHMA/NA and MHMA/AD (representative of good MAO cat-
echolamine metabolism) positively correlate with low histamine 
levels. If this is so, that good MAO metabolism (facilitated by 
FAD) is ongoing in the homozygous MTHFR polymorphism set-
ting, this lends weight to the concept that FAD may be conserved 
and readily available for MAO activity when the MTHFR enzyme 
is inactive. It explains why no correlative relationship is found 
between elevated NA/MHMA and AD/MHMA ROCs and the 
homozygous 677TT MTHFR polymorphism in the full sample 
set and why catecholamine entities as a whole hold no significant 
correlates with the polymorphism within the split sample set.
Since FAD is reported to be more easily dislodged from the 
structure of the MTHFR 677TT coded enzyme in its thermo-
labile, low-activity form (105), one evolutionary benefit of this 
homozygous polymorphism may be its provision of dislodged 
un-utilized FAD for sustaining MAO enzyme activity and keeping 
vitamin B6 and D activated. This could be a useful gene adaptive 
strategy in famine environments devoid of meat and yellow veg-
etables such as previously linked to famine and the schizophrenia 
condition (106). This strategy may further provide some hedging 
against oxidative stress, which is another recognized feature of 
schizophrenia (107).
MThFr homozygous Polymorphism, 
elevated B12 levels and risk of 
homocysteine-Driven BhMT hyperactivity 
and an Over-Methylation state
In relationship to vitamin B6 and folate, HCY a significant cor-
relate within the MTHFR homozygous data set and findings from 
two other studies have identified that the relationship between 
riboflavin and HCY is dependent on the MTHFR C677 homozy-
gous polymorphism (108). In the split data set for the MTHFR 
667TT polymorphism, vitamin levels of folate were found to be 
low in relationship to high HCY (Significance index 84), and 
B12 (Significance index 45), high-lighting the potential of this 
homozygous polymorphism to contribute to HCY-related cardio-
vascular disease. When HCY is elevated and its usual metabolism 
route via MS is inoperative due to insufficient 5MTHF from the 
inactive, MTHFR 677TT coded enzyme, its metabolism must 
proceed by the betaine [trimethyl glycine (TMG)] degradation 
pathway, served by the BHMT enzyme (94). This activity pro-
duces DMG that requires FAD to de-methylate itself. Since lack 
of correlates for catecholamines in the split sample infers that 
MAO activity in good in the MTHFR 677TT genotype setting, 
this also implies that there is sufficient FAD cofactor available 
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for other enzyme reactions. In particular, remethylation of DMG 
can now proceed and with it the betaine degradation pathway, 
whereby elevated HCY can drive BHMT to produce high levels 
of SAMe from Methionine. High levels of SAMe will in turn drive 
catecholamine COMT metabolism (Figure 4) Therefore, in such 
a flavin-sufficient, methylating state, there is a theoretical risk 
that catecholamines will be excessively degraded by both MAO 
and COMT to a degree that depleted catecholamine levels lead 
to depression and adrenal re-synthesis exhaustion with cognitive 
and motor retardation (17, 109). In addition high free copper 
levels disturb thyroid function, adrenal hormone production and 
lower DA and histamine levels whilst SAMe-driven histamine 
metabolism also promotes low histamine levels – effects that all 
promote apathy and negative symptoms in schizophrenia.
summary of Findings and Further 
implications
Taken together, findings from this study implicate the existence 
of two contrasting forms of functional psychosis, the differing 
characteristics of which are summarized in Table 9. One form 
associated with low flavin and folate availability with a normal 
MTHFR enzyme polymorphism and the other form associated 
with a homozygous MTHFR 677TT polymorphism in the pres-
ence of elevated free copper. The two forms may be evolutionarily 
linked, as the homozygous MTHFR 677TT polymorphism may be 
a gene adaptation designed to conserve body flavin in the setting 
of famine conditions (110). Other researchers have also come to a 
similar, though non-specific conclusion that the 677TT MTHFR 
polymorphism may protect against tissue injury or unbalanced 
vitamin intake (111).
Though these findings highlight Flavin deficiency, they 
broadly imply that that, there is scope for targeted, sequenced 
nutritional support in functional psychoses such as schizophrenia 
and schizoaffective disorder. Several studies have indicated wide-
spread riboflavin (vitamin B2) deficiency in psychiatric patients 
as well as in youth and elderly in industrialized countries with 
an imputed role for flavin supplementation (112). In particular, 
early zinc, copper and riboflavin level assessments, vitamin 
level assessments and gut vitamin absorption assessments with 
mucosal rehabilitation could be considered primary initiatives 
to re-establish good vitamin absorption, in functional psychosis 
treatment. In the non-polymorphism MTHFR677C → T gene-
variant guided setting, once reasonable diet and mucosal function 
has been restored, riboflavin supplementation and if necessary 
supplementation of other vitamins (methylfolate, and vitamins 
B6, and D) and zinc can be introduced. Dietary riboflavin sources 
should also be considered. These include almonds, whole grains, 
wheat germ, wild rice, mushrooms, soybeans, brewer’s yeast, milk, 
yogurt, eggs, broccoli, Brussels sprouts, and spinach. Riboflavin 
supplementation has been demonstrated to restore glutathione 
activity (61) and N acetyl cysteine, an intermediate substrate in 
the transulfuration pathway from homocysteine to glutathione 
(Figure  1), may also offset glutathione synthesis deficiency in 
settings of oxidative stress (113). Such combination therapy has 
already been proposed with zinc and B6 supplementation trialed 
to reduce elevated HPL levels (114). Zinc supplementation reduces 
excess free copper and moderates copper effects in relationship 
to neurotoxicity, oxidative stress, thyroid damage and poor FMN 
synthesis (115, 116). The relationship of low ceruloplasmin to 
high free copper levels and Wilson’s disease is also well-known 
and are deserving of greater attention in psychosis research 
(117). Biochemically targeted, longitudinal therapeutic trials are 
also required in this propitious field of precision biochemical 
remediation for schizophrenia and schizoaffective psychosis.
Findings from the MTHFR heterozygous data-set have not 
been discussed in detail in this manuscript due to the fact that 
correlates within this third data-set generally reflected findings in 
the no-polymorphism state, with some overlaps with the homozy-
gous state findings. This is may be because the 677CT MTHFR 
adaptation is attempting to modify the extreme biochemical 
effects of either under- or over-methylation. Furthermore, the fact 
TaBle 9 | summary comparison of two main MThFr variant – 
biochemical types, based upon combined findings from correlation, 
seM, and significance indices [sis] for caseness (Tables 7 and 8; 
Figures 3 and 4).
characteristic MThFr homozygous MThFr-no 
polymorphism
Flavins FMN-FAD Sufficient or + Low
Vitamin levels Sufficient or + Low
Methylation profile pattern Sufficient or + Low
Severity CGI + +++
Disability (GAF) + +++
Catecholamines AD marginal +++ (DA and NA 
predominate)
With low folate ++
With low vitamin B6 ++
With low vitamin D ++
Noradrenaline − ++++
5HIAA excretion − ++
HPL oxidative stress 
marker
+ ++++
High % free Cu/Zn ratio + −
GAF + With high DA +
CGI +
Low RC folate + ++
With high homocysteine 
++
With psychosis caseness 
++
With high vitamin B12 +
High homocysteine +++ ++
With low vitamin B6 + With low activated vitamin 
B6 +
With low folate +
Low vitamin B6 − ++
With low SOFAS ++
With high CGI ++
With DOI ++
Low vitamin D levels − ++
With SIR +++
With CGI ++
With low SOFAS ++
Serum histamine − ++
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that three different forms of gene code for the MTHFR enzyme at 
position 677 and that flow-on biochemical effects of two of these 
(wild-type, and homozygous) form contrasting biochemical phe-
notypes within a MTHFR 677C → T split data-set, may explain 
why contrasting results are often obtained from psychiatric 
research where different biochemical effects of MTHFR 677C-T 
phenotypes in populations under examination are combining to 
obscure research outcomes. These findings therefore imply the 
need to take these MTHFR677 C → T biochemical phenotypes 
well into account in research data examination and outcome 
comparison.
limitations
This study used multiple exclusion criteria to obtain a highly 
characterized group of case and control participants. Limitations 
of this study have been outlined in previous publications relating 
to findings from the Mental Health Biomarker Project (1, 2) and 
relate to issues of bias inherent in a case–control study, smok-
ing, and medication. With respect to confounding effects from 
medications received by only a few case participants in this study, 
oral contraceptives have been noted to lower vitamin B6 levels 
and sodium valproate noted to lower folic acid levels and raise 
HCY levels (118). Interestingly, some tricyclic antidepressants 
and antipsychotics such as chlorpromazine have been reported 
to inhibit synthesis of FAD from riboflavin, by the flavokinase 
enzyme (119). Though no patients in this study were on such 
antidepressants, research on riboflavin-related enzyme dynamics 
are certainly now warranted for a wider range of antipsychotics.
During SEM data analysis, 66 parameters were estimated 
from a covariance matrix of 17 independent variables and 153 
data points were derived from 134 observations, so data available 
for estimation of SEM model parameters was minimal. Although 
significant correlates were discovered within the split data set for 
MTHFR 677TT, the overall sample number was low relative to 
the other part of the data set due to the lesser incidence of this 
polymorphism. Findings from the MTHFR heterozygous data-
set have not been discussed in detail in this manuscript due to the 
fact that correlates within this data-set occupied an overlapping 
position between the other two data sets. Unknown thyroid hor-
mone status of individuals in this study is a further limiting factor 
of potential relevance since diminished FMN–FAD effect hepatic 
flavoprotein enzyme activity which may relate to hypothyroidism 
and unavailability of thyroid hormone for priming FMN synthe-
sis (120). This study’s finding that MTHFR 677TT coding acts as a 
threshold for two flavin-related phenotypes does not exclude the 
possibility of a number of other gene variants co-acting with the 
MTHFR 677 gene to effect threshold risk factors for psychosis.
sUMMarY anD cOnclUsiOn
Dynamic biochemistry understandings derived from three 
types of data analysis were aligned in this study and provided 
support for the existence of two genotype-directed biochemical 
phenotypes for functional psychosis. One phenotype is linked 
with low folate and flavin availability associated with wild-type 
gene coding of the MTHFR enzyme. The other enzyme form is 
coded by a homozygous MTHFR 677TT gene-polymorphism, 
linked to elevated free copper and HCY. These two different 
flavin-related biochemical phenotypes have correlative findings 
suggesting that MTHFR 677CT status has potential to influence 
biochemistry in two opposing directions – under-methylation 
and over-methylation.
In the first no-polymorphism phenotype, low folate intake or 
low FAD availability with normal MTHFR activity, lack of folate-
substrate and FAD-cofactor for the MTHFR enzyme, retards 
both folate and methionine cycles creating an under-methylation 
setting. In the methionine cycle FAD cofactor deficiency also 
retards cobalamin reactivation, which retards HCY conver-
sion to methionine. FMN–FAD deprivation also retards MAO 
activity, leading to catecholamine elevation. Vitamin D, B6, and 
glutathione also lack flavin activation, creating an environment of 
vitamin inactivity and oxidative stress.
In the second homozygous phenotype, the relatively inactive 
MTHFR 677TT polymorphism seeks to prevent this scenario by 
allowing its enzyme-unutilized FAD cofactor to sufficiently acti-
vate vitamin D, B6, cobalamin and glutathione. However, despite 
this activation facility, it can still not provide sufficient methyla-
tion product to run the methylation cycle. In this setting, HCY 
is elevated and an alternative, FAD-dependent channel is opened 
up across the methylation cycle to allow high, trapped levels of 
HCY to be metabolized. Hyper-activation of this HCY-driven 
pathway results in excessive SAMe production with attendant 
risk of low catecholamines, low histamine and ultimately adrenal 
exhaustion.
These understandings increase knowledge of the genetic and 
biochemical nature of schizophrenia and schizoaffective psycho-
sis. The two contrasting phenotypes provide a structural basis 
for data-interpretation in future Psychiatry research and also 
point toward MTHFR 677 C → T gene-guided therapy as part of 
rational, biochemical treatment solutions in the clinic.
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integrated theory and requested data in relationship to MTHFR 
polymorphism activity and the correlation of variables for 
homocysteine, histamine, elevated Noradrenaline, Adrenaline 
and Dopamine, % free copper, ceruloplasmin, zinc, vitamin 
B6, vitamin D, vitamin B12, monoamine oxide activity (NA/
MHMA and AD/MHMA), and FMN/FAD availability. SF-W 
also requested confirmation of Flavin role by pathway analysis 
and discovered the different patterns of biochemical phenotypes 
between MTHFR 677C →  T-no polymorphism status (under-
methylation) and MTHFR homozygous polymorphism (over-
methylation) within schizophrenia and schizoaffective disorder. 
Also the no-polymorphism and homozygous MTHFR relation-
ships to the heterozygous gene form and to other biochemical 
variables and their ROCs with respect to psychosis caseness, 
severity, disability, and other functional parameters.
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